SABCS 2022 EMERALD Phase 3 Trial Updated Results by Duration of Prior CDK4/6i: Elacestrant vs. SoC ET in Patients With ER+/HER2- mBC

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

SABCS 2022 EMERALD Phase 3 Trial Updated Results by Duration of Prior CDK4/6i: Elacestrant vs. SoC ET in Patients With ER+/HER2- mBC

By SABCS 2022 Conference Coverage FEATURING Hung Khong

1,628 views

December 14, 2022

This video was recorded prior to FDA approval of ORSERDU™ (elacestrant) on January 27, 2023 ...
read more ↘ in ER+/ HER2-, ESR1-mutated advanced or metastatic breast cancer who have progressed on at least 1 line of endocrine therapy
↖ read less

1 Comment